Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
82.6M
-
Shares change
-
+2.34M
-
Total reported value, excl. options
-
$2B
-
Value change
-
+$63.5M
-
Put/Call ratio
-
0.39
-
Number of buys
-
83
-
Number of sells
-
-43
-
Price
-
$24.18
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q2 2020
155 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q2 2020.
Denali Therapeutics Inc. - Common Stock (DNLI) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.6M shares
of 145M outstanding shares and own 56.89% of the company stock.
Largest 10 shareholders include Crestline Management, LP (13.6M shares), BAILLIE GIFFORD & CO (9.28M shares), Flagship Pioneering Inc. (7.98M shares), VANGUARD GROUP INC (7.09M shares), BlackRock Inc. (6.26M shares), FMR LLC (4.81M shares), Temasek Holdings (Private) Ltd (4.41M shares), GILDER GAGNON HOWE & CO LLC (3.39M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.62M shares), and STATE STREET CORP (2.25M shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.